We are international

Call the IMF Hotline. We are here for you. The IMF Office is open from 8:00AM - 5:00PM PST, Monday-Friday.

If you have a question, call the IMF InfoLine at (800) 452-CURE (800-452-2873) in the US and Canada. The InfoLine is open from 9:00 - 4:00 PT Monday - Friday. Elsewhere call (818) 487-7455. You can also contact us via the web.
IMF - Home Page
    next      view all

ARROW clinical trial fact sheet
A Randomized, Open-label, Phase III Study in Subjects with Relapsed and Refractory Multiple Myeloma Receiving Carfilzomib (Kyprolis®) in Combination with Dexamethasone, Comparing Once-weekly Versus Twice-weekly Carfilzomib Dosing

Register for the Living Well with Myeloma: NLB Members Answers Key Patient and Caregiver Questions

Beth Faiman, PhD, MSN, APRN-BC, AOCN
Cleveland Clinic Taussig Cancer Institute
Multiple Myeloma Program
Cleveland, Ohio

Teresa Miceli, RN, BSN, OCN
Mayo Clinic-Rochester
Rochester, Minnesota

Exciting Silent Auctions Items Continue to Stack Up for IMF's 9th Annual Comedy Celebration
Not only is this year's 9th Annual Comedy Celebration gala packed with talented comics Tig Notaro, Fred Willard, and Heather McDonald, but the number of silent auction items up for bidding continues to grow! Unique experiences like a visit to the “NBC Nightly News with Lester Holt” broadcast control booth; a visit to the set of “New Girl,” starring Zooey Deschanel; and an autographed guitar signed by Joe Walsh have all been added. Remember, proceeds from the event benefit the Peter Boyle Research Fund, as well as support the Black Swan Research Initiative®, the IMF's collaborative project aimed at developing the first definitive cure for myeloma. The night kicks off at 6 pm, next Saturday, October 10 at the Wilshire Ebell Theatre & Club in Los Angeles.

Black Swan Research Initiative Team Member Wins Prestigious Award
Dr. Bruno Paiva, a member of IMF's Black Swan Research Initiative team, won the Bart Barlogie Young Investigator Award on Saturday at the International Myeloma Workshop in Rome. Dr. Paiva's primary research area is the assessment of minimal residual disease (MRD), and in his blog this week, IMF Chairman Dr. Brian Durie writes, "This award acknowledges Bruno individually and the importance of the MRD approach to searching for a cure for myeloma."

Janssen’s daratumumab accepted for accelerated CHMP assessment for treatment of European patients with heavily pre-treated multiple myeloma
Janssen-Cilag International NV announced on September 25, 2015 that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has accepted its request for an accelerated assessment of the daratumumab Marketing Authorisation Application (MAA). This acceptance follows the earlier regulatory submission of a MAA which seeks authorisation of daratumumab as a single agent for the treatment of patients with relapsed and refractory multiple myeloma and is currently pending validation by the EMA.

Myeloma Canada Seeks US Patient and Caregiver Input

The survey is about your experience with carfilzomib (Kyprolis®). Your help with this important matter is greatly appreciated, as we do not have Canadian patients, outside of a limited number of clinical trials, who have used the treatment this way.

New Study Investigates Carfilzomib, Pomalidomide, and Dexamethasone in Relapsed and/or Refractory Myeloma
The results of the first clinical trial to investigate carfilzomib (Kyprolis®), pomalidomide (Pomalyst®), and dexamethasone (CPD) in multiple myeloma were published last week in the journal BLOOD . IMF Chairman Dr. Brian Durie, co-author of the study, calls the phase I-II results “remarkably good.” According to Dr. Durie, the well-tolerated regime produces remissions lasting approximately one year, and overall survival of close to two years, in the very-poor-risk setting of double refractory disease in which patients are resistant to both lenalidomide (Revlimid®) and bortezomib (Velcade®).

Takeda to Highlight Ixazomib Clinical Development Program at Upcoming International Myeloma Workshop
Takeda Pharmaceutical Company Limited on September 22, 2015 announced that it will highlight the ixazomib clinical development program during multiple poster sessions at the upcoming 15th International Myeloma Workshop (IMW 2015) to be held in Rome, Italy, from September 23 to 26, 2015.

FDA Grants Priority Review for Amgen's sNDA for Expanded Labeling of Kyprolis® in Relapsed Multiple Myeloma
The US Food and Drug Administration (FDA) has agreed for priority review of Amgen’s supplemental new drug application (sNDA) for expanded labeling of Kyprolis (carfilzomib) in relapsed multiple myeloma.

Huge Interest in Toxic Chemicals Triggered by Last Week's Blog: Follow-up Notes
In a follow-up to last week's blog about Agent Orange, IMF Chairman Dr. Brian Durie writes that a new report suggesting a link between home pesticide use and the risk of childhood cancers - especially blood cancers such as leukemia and lymphoma - could have implications for adults. Also, news that New York Times food columnist Mark Bittman is putting down his pen to take action.

    next      view all